secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2026-02-03T23:59:59+00:00
Accession:  0001193125-26-034464
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna appoints Mayo Pujols as CTO; Karen Walker retires effective Feb 9, 2026
-------------------------------------------------------------------------------

- Mayo Pujols named CTO effective Feb 9, bringing 30+ years in CAR T and cell therapy manufacturing.
- Outgoing CTO Karen Walker retires; will consult on BLA submission for miv-cel in stiff person syndrome.
- Pujols receives an inducement option for 300,000 shares vesting over 4 years under the 2024 Inducement Plan.
- The inducement plan was amended to increase authorized shares by 1,000,000 to 5,000,000 total.
- Kyverna advances toward potential commercial launch of miv-cel for autoimmune diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526034464/0001193125-26-034464-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526034464/kytx-20260129.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-034464

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer